GSK press releases Follow Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B Nearly 1 million people in Japan live with chronic hepatitis B, a leading cause of liver cancer https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-regulatory-review-in-japan/ gsk.com
